FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Marshall Ken W.  (Last) (First) (Middle)  C/O AQUESTIVE THERAPEUTICS, INC.  30 TECHNOLOGY DRIVE  (Street)  WARREN NJ 07059  (City) (State) (Zip)					3. I 03/	2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [ AQST ]  3. Date of Earliest Transaction (Month/Day/Year) 03/11/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ir	Relationship of Reporting Person(s) to Issuer neck all applicable)  Director 10% Owner Officer (give title Other (specify below) SVP, Chief Commercial Officer  Individual or Joint/Group Filing (Check Applicable le)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				oner specify er
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,		Code (Ins	str.		ties Acquire I Of (D) (Ins (A) or (D)	tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reportec Transact (Instr. 3 a	s ally following I ion(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	ate, 1	i. Transaction Code (Instr.				6. Date Exercisa Expiration Date (Month/Day/Year			7. Title and of Securiti Underlying Derivative (Instr. 3 and	es J Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Non- Qualified Stock Option (right to buy)	\$5.3	03/11/2021			A		40,000		(1)	03	3/11/2031	Common Stock	40,000	\$0	40,000	)	D	

## **Explanation of Responses:**

1. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

## Remarks:

/s/ Robert Arnold, as Attorney-03/15/2021

In-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.